Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.47 |
| ▸ | TGM2 | P21980 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | EGFR | P00533 | 2/20 | 0.43 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14889158 | 0.83 | LMNA (0.48) | SMN1; SMN2GAAKMT2AALDH1A1LMNA | |
| SCHEMBL5319263 | 0.81 | CA2 (0.56) | CTBP2KMT2ARAB9ALMNA | |
| SCHEMBL6451970 | 0.81 | GAA (0.50) | SMN1; SMN2GAACTBP2TDP1POLB | |
| SCHEMBL13000434 | 0.79 | CTBP2 (0.47) | SMN1; SMN2GAACTBP2TGM2TDP1 | |
| SCHEMBL13475778 | 0.79 | MEN1 (0.38) | SMN1; SMN2TGM2KMT2AALDH1A1 | |
| Water SCHEMBL17802313 | 0.79 | GAA (0.48) | SMN1; SMN2GAACTBP2TDP1POLB | |
| SCHEMBL669706 | 0.78 | CES1 (0.56) | GAACTBP2TGM2KMT2AALDH1A1 | |
| SCHEMBL8825675 | 0.78 | ALDH1A1 (0.50) | SMN1; SMN2GAATDP1POLBAPEX1 | |
| Ammonia Solution, Strong SCHEMBL11111905 | 0.77 | CES1 (0.54) | GAACTBP2TGM2KMT2AALDH1A1 | |
| SCHEMBL8194656 | 0.76 | CTBP2 (0.53) | SMN1; SMN2GAACTBP2TDP1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11026920-B2 | Use of NK-1 receptor antagonist serlopitant in pruritus | VYNE THERAPEUTICS INC. (US) | 2021-06-08 | — | — | US | disclosed |
| US-20200306224-A1 | USE OF NK-1 RECEPTOR ANTAGONIST SERLOPITANT IN PRURITUS | VYNE THERAPEUTICS INC. | 2020-10-01 | — | — | US | disclosed |
| US-10702499-B2 | Use of NK-1 receptor antagonists in pruritus | MENLO THERAPEUTICS INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-10617671-B2 | Use of NK-1 receptor antagonist serlopitant in pruritus | MENLO THERAPEUTICS INC. (US) | 2020-04-14 | — | — | US | disclosed |
| US-20200054603-A1 | USE OF NK-1 RECEPTOR ANTAGONIST SERLOPITANT IN PRURITUS | VYNE THERAPEUTICS INC. (F/K/A MENLO THERAPEUTICS INC. AND SUCCESSOR-IN-INTEREST TO VYNE PHARMACEUTICALS LTD., F/K/A FOAMIX PHARMACEUTICALS LTD.) | 2020-02-20 | — | — | US | disclosed |
| US-20200054604-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS IN PRURITUS | VYNE THERAPEUTICS INC. (F/K/A MENLO THERAPEUTICS INC. AND SUCCESSOR-IN-INTEREST TO VYNE PHARMACEUTICALS LTD., F/K/A FOAMIX PHARMACEUTICALS LTD.) | 2020-02-20 | — | — | US | disclosed |
| US-10278952-B2 | Use of NK-1 receptor antagonists in pruritus | MENLO THERAPEUTICS INC. (US) | 2019-05-07 | — | — | US | disclosed |
| US-10278953-B2 | Use of NK-1 receptor antagonist serlopitant in pruritus | MENLO THERAPEUTICS INC. (US) | 2019-05-07 | — | — | US | disclosed |
| US-20180325867-A1 | USE OF NK-1 RECEPTOR ANTAGONIST SERLOPITANT IN PRURITUS | VYNE THERAPEUTICS INC. (F/K/A MENLO THERAPEUTICS INC. AND SUCCESSOR-IN-INTEREST TO VYNE PHARMACEUTICALS LTD., F/K/A FOAMIX PHARMACEUTICALS LTD.) | 2018-11-15 | — | — | US | disclosed |
| US-20180325866-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS IN PRURITUS | VYNE THERAPEUTICS INC. (F/K/A MENLO THERAPEUTICS INC. AND SUCCESSOR-IN-INTEREST TO VYNE PHARMACEUTICALS LTD., F/K/A FOAMIX PHARMACEUTICALS LTD.) | 2018-11-15 | — | — | US | disclosed |
| US-7217731-B2 | Hydroisoindoline tachykinin receptor antagonists | MERCK & CO., INC. (US) | 2007-05-15 | — | — | US | disclosed |
| US-20070015923-A1 | Process for making hydroisoindoline tachykinin receptor antagonists | MERCK SHARP & DOHME CORP. | 2007-01-18 | — | — | US | disclosed |
| US-20070015923-A1 | Process for making hydroisoindoline tachykinin receptor antagonists | MERCK SHARP & DOHME CORP. | 2007-01-18 | — | — | US | disclosed |
| US-20070015923-A1 | Process for making hydroisoindoline tachykinin receptor antagonists | MERCK SHARP & DOHME CORP. | 2007-01-18 | — | — | US | disclosed |
| WO-2007008564-A1 | PROCESS FOR MAKING HYDROISOINDOLINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2007-01-18 | — | — | WO | disclosed |
| WO-2007008564-A1 | PROCESS FOR MAKING HYDROISOINDOLINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2007-01-18 | — | — | WO | disclosed |
| WO-2007002457-A2 | HYDROISOINDOLINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| EP-1711465-A1 | HYDROISOINDOLINE TACHYKININ RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2006-10-18 | — | — | EP | disclosed |
| WO-2005073191-A1 | HYDROISOINDOLINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2005-08-11 | — | — | WO | disclosed |
| US-20050165083-A1 | Hydroisoindoline tachykinin receptor antagonists | VYNE THERAPEUTICS INC. (F/K/A MENLO THERAPEUTICS INC. AND SUCCESSOR-IN-INTEREST TO VYNE PHARMACEUTICALS LTD., F/K/A FOAMIX PHARMACEUTICALS LTD.) | 2005-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165083-A1 | Hydroisoindoline tachykinin receptor antagonists | TACR1, TACR2, NPSR1 | SMN1; SMN2 3498/4885GAA 1415/4885CTBP2 4492/4885 |
| US-10702499-B2 | Use of NK-1 receptor antagonists in pruritus | TACR1, CYSLTR1, HRH3 | SMN1; SMN2 4205/4885GAA 3047/4885CTBP2 4811/4885 |
| US-10278952-B2 | Use of NK-1 receptor antagonists in pruritus | TACR1, CYSLTR1, HRH3 | SMN1; SMN2 4205/4885GAA 3047/4885CTBP2 4811/4885 |
| US-10617671-B2 | Use of NK-1 receptor antagonist serlopitant in pruritus | TACR1, CYSLTR1, NPSR1 | SMN1; SMN2 3898/4885GAA 3198/4885CTBP2 4809/4885 |
| US-20200054603-A1 | USE OF NK-1 RECEPTOR ANTAGONIST SERLOPITANT IN PRURITUS | TACR1, CYSLTR1, NPSR1 | SMN1; SMN2 3898/4885GAA 3198/4885CTBP2 4809/4885 |
| US-20200054604-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS IN PRURITUS | TACR1, CYSLTR1, HRH3 | SMN1; SMN2 4205/4885GAA 3047/4885CTBP2 4811/4885 |
| US-20200306224-A1 | USE OF NK-1 RECEPTOR ANTAGONIST SERLOPITANT IN PRURITUS | TACR1, CYSLTR1, NPSR1 | SMN1; SMN2 3898/4885GAA 3198/4885CTBP2 4809/4885 |
| US-20180325866-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS IN PRURITUS | TACR1, CYSLTR1, HRH3 | SMN1; SMN2 4205/4885GAA 3047/4885CTBP2 4811/4885 |
| US-20070015923-A1 | Process for making hydroisoindoline tachykinin receptor antagonists | TACR1, TACR2, NPSR1 | SMN1; SMN2 2949/4885GAA 1326/4885CTBP2 4148/4885 |
| US-11026920-B2 | Use of NK-1 receptor antagonist serlopitant in pruritus | TACR1, CYSLTR1, NPSR1 | SMN1; SMN2 3898/4885GAA 3198/4885CTBP2 4809/4885 |
| US-10278953-B2 | Use of NK-1 receptor antagonist serlopitant in pruritus | TACR1, CYSLTR1, NPSR1 | SMN1; SMN2 3898/4885GAA 3198/4885CTBP2 4809/4885 |
| US-20180325867-A1 | USE OF NK-1 RECEPTOR ANTAGONIST SERLOPITANT IN PRURITUS | TACR1, CYSLTR1, NPSR1 | SMN1; SMN2 3898/4885GAA 3198/4885CTBP2 4809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.